Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | melanin-concentrating hormone receptor 1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | oxidoreductase | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0086 | 1 | 0.5 |
Echinococcus multilocularis | protein MICAL 3 | 0.0086 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0086 | 1 | 0.5 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0086 | 1 | 1 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0086 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0086 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0075 | 0.7913 | 0.7913 |
Leishmania major | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0086 | 1 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0049 | 0.2762 | 1 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0086 | 1 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0049 | 0.2762 | 1 |
Mycobacterium ulcerans | oxidoreductase | 0.0086 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0086 | 1 | 0.5 |
Echinococcus granulosus | protein MICAL 3 | 0.0086 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0086 | 1 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0086 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0086 | 1 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0086 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | monoxygenase | 0.0086 | 1 | 1 |
Trypanosoma brucei | Monooxygenase, putative | 0.0086 | 1 | 1 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0086 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CL (ADMET) | 0 | Metabolic stability assessed as intrinsic clearance in human liver microsomes | ChEMBL. | 17532215 |
IC50 (functional) | Antagonist activity at human MCHR1 expressed in HEK293 cells assessed as [35S]GTPgammaS accumulation | ChEMBL. | 17532215 | |
IC50 (functional) | 0 | Antagonist activity at human MCHR1 expressed in HEK293 cells assessed as [35S]GTPgammaS accumulation | ChEMBL. | 17532215 |
IC50 (binding) | = 0.571 uM | Displacement of [125I]MCH from human MCHR1 expressed in HEK293 cells | ChEMBL. | 17532215 |
IC50 (binding) | = 0.571 uM | Displacement of [125I]MCH from human MCHR1 expressed in HEK293 cells | ChEMBL. | 17532215 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.